Performance of a 31-gene expression profile test in cutaneous melanomas of the head and neck.
Adult
Aged
Aged, 80 and over
Cohort Studies
Disease-Free Survival
Female
Gene Expression Profiling
Head and Neck Neoplasms
/ genetics
Humans
Kaplan-Meier Estimate
Lymph Node Excision
/ methods
Lymph Nodes
/ pathology
Lymphatic Metastasis
Male
Melanoma
/ genetics
Middle Aged
Multivariate Analysis
Neoplasm Invasiveness
/ pathology
Neoplasm Staging
Proportional Hazards Models
Retrospective Studies
Risk Assessment
Sentinel Lymph Node Biopsy
Skin Neoplasms
/ genetics
Survival Analysis
United States
cutaneous melanoma
gene expression profiling
metastasis
prognosis
staging
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
06
11
2017
revised:
23
03
2018
accepted:
05
07
2018
pubmed:
30
1
2019
medline:
10
10
2020
entrez:
30
1
2019
Statut:
ppublish
Résumé
We report the performance of a gene expression profile test to classify the recurrence risk of cutaneous melanoma tumors of the head and neck as low-risk Class 1 or high-risk Class 2. Of note, 157 primary head and neck cutaneous melanoma tumors were identified. Survival analyses were performed using Kaplan-Meier and Cox methods. Gene expression profile class and node status stratified tumors into significantly different 5-year survival groups by Kaplan-Meier method (P < .0001 for all end points), and both were independent predictors of recurrence in multivariate analysis. Overall, 74% of distant metastases and 88% of melanoma-specific deaths had Class 2 risk. The gene expression profile test identifies cases at increased risk for metastasis and death independent of a clinically or pathologically negative nodal status, suggesting that incorporation of this molecular tool could improve clinical management of patients with head and neck cutaneous melanoma, especially in those with a negative sentinel lymph node biopsy.
Sections du résumé
BACKGROUND
We report the performance of a gene expression profile test to classify the recurrence risk of cutaneous melanoma tumors of the head and neck as low-risk Class 1 or high-risk Class 2.
METHODS
Of note, 157 primary head and neck cutaneous melanoma tumors were identified. Survival analyses were performed using Kaplan-Meier and Cox methods.
RESULTS
Gene expression profile class and node status stratified tumors into significantly different 5-year survival groups by Kaplan-Meier method (P < .0001 for all end points), and both were independent predictors of recurrence in multivariate analysis. Overall, 74% of distant metastases and 88% of melanoma-specific deaths had Class 2 risk.
CONCLUSION
The gene expression profile test identifies cases at increased risk for metastasis and death independent of a clinically or pathologically negative nodal status, suggesting that incorporation of this molecular tool could improve clinical management of patients with head and neck cutaneous melanoma, especially in those with a negative sentinel lymph node biopsy.
Identifiants
pubmed: 30694001
doi: 10.1002/hed.25473
pmc: PMC6667900
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
871-879Subventions
Organisme : Castle Biosciences, Inc.
Pays : International
Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Head Neck. 2019 Apr;41(4):871-879
pubmed: 30694001
Ann Surg Oncol. 2017 Feb;24(2):355-361
pubmed: 27660259
Pigment Cell Melanoma Res. 2011 Apr;24(2):345-51
pubmed: 21324100
BMC Cancer. 2018 Feb 5;18(1):130
pubmed: 29402264
Eur J Cancer. 2015 Mar;51(5):653-67
pubmed: 25638778
Head Neck. 2010 Dec;32(12):1686-92
pubmed: 20848412
J Natl Compr Canc Netw. 2016 Apr;14(4):450-73
pubmed: 27059193
Curr Treat Options Oncol. 2004 Jun;5(3):185-94
pubmed: 15115647
N Engl J Med. 2014 Feb 13;370(7):599-609
pubmed: 24521106
Ann Surg Oncol. 2001 Oct;8(9 Suppl):41S-43S
pubmed: 11599897
J Clin Oncol. 2009 Dec 20;27(36):6199-206
pubmed: 19917835
Br J Surg. 2004 Jun;91(6):673-82
pubmed: 15164434
Ann Surg Oncol. 2016 Mar;23(3):1012-8
pubmed: 26586498
N Engl J Med. 2006 Sep 28;355(13):1307-17
pubmed: 17005948
Rev Laryngol Otol Rhinol (Bord). 2014;135(3):115-20
pubmed: 26521353
J Am Acad Dermatol. 2016 Sep;75(3):516-524
pubmed: 27183845
JAMA Surg. 2013 May;148(5):456-61
pubmed: 23325294
Head Neck. 2008 Oct;30(10):1284-94
pubmed: 18704971
Clin Cancer Res. 2015 Jan 1;21(1):175-83
pubmed: 25564571
Head Neck. 2016 Dec;38(12):1752-1758
pubmed: 27407058
N Engl J Med. 2017 Jun 8;376(23):2211-2222
pubmed: 28591523
Melanoma Res. 2017 Aug;27(4):335-341
pubmed: 28296712
Ann Surg Oncol. 2010 Mar;17(3):709-17
pubmed: 19967459
Int J Oncol. 2006 Jul;29(1):139-45
pubmed: 16773193
Ann Surg Oncol. 2013 Sep;20(9):3089-97
pubmed: 23649930
G Chir. 2014 May-Jun;35(5-6):149-55
pubmed: 24979109
Cancer Causes Control. 2001 Jan;12(1):69-82
pubmed: 11227927
JAMA. 2016 Apr 19;315(15):1600-9
pubmed: 27092830
J Am Acad Dermatol. 2015 May;72(5):780-5.e3
pubmed: 25748297
Arch Dermatol. 1999 Dec;135(12):1472-6
pubmed: 10606052
Ann Surg Oncol. 2006 Dec;13(12):1655-63
pubmed: 17016755
J Am Acad Dermatol. 2017 May;76(5):818-825.e3
pubmed: 28110997
Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2222-31
pubmed: 24083994
Ann Surg. 2008 Sep;248(3):378-86
pubmed: 18791358
Head Neck. 2016 Apr;38 Suppl 1:E754-60
pubmed: 25914266
Arch Otolaryngol Head Neck Surg. 2003 Jan;129(1):61-5
pubmed: 12525196
Am J Surg. 1995 Nov;170(5):461-6
pubmed: 7485733